Sigyn Therapeutics, Inc. (OTCMKTS:SIGY) Short Interest Update

Sigyn Therapeutics, Inc. (OTCMKTS:SIGY) was the recipient of a large increase in short interest during the month of May. As of May 29th, there was short interest totaling 32,362 shares, an increase of 1,083.3% from the May 14th total of 2,735 shares. Approximately 5.9% of the shares of the stock are short sold. Based on an average daily trading volume, of 54,195 shares, the days-to-cover ratio is currently 0.6 days.

Sigyn Therapeutics Stock Down 1.3%

Shares of SIGY stock traded down $0.00 during mid-day trading on Thursday, hitting $0.04. 9,900 shares of the company’s stock were exchanged, compared to its average volume of 106,937. Sigyn Therapeutics has a fifty-two week low of $0.01 and a fifty-two week high of $5.00. The stock has a 50-day simple moving average of $0.04 and a two-hundred day simple moving average of $0.61. The stock has a market cap of $99,060.00, a price-to-earnings ratio of -0.01 and a beta of -0.06.

Sigyn Therapeutics Company Profile

Sigyn Therapeutics, Inc, a development-stage company, provides therapeutic solutions in the United States. Its lead product candidate is Sigyn Therapy, a broad-spectrum blood purification technology designed to treat pathogen-associated inflammatory disorders, including endotoxemia and inflammation in end-stage renal disease patients, sepsis, community acquired pneumonia, drug resistant bacterial infections, and emerging pandemic threats. The company is also involved in evaluating the Sigyn Therapy to address various therapeutic targets, including endotoxin; peptidoglycan and lipoteichoic acid; viral pathogens; hepatic toxins; and tumor necrosis factor alpha, interleukin-1 beta, and interleukin 6, which are pro-inflammatory cytokines.